This year’s flagship event will gather top EU, US, Asia and global regulators, officials, healthcare actors as well as industry leaders, to foster open exchange and debate on the role of the biosimilar & biologics medicines sector.
The BioTech Pharma Summit: Gut-Brain Axis 2018 will be dedicated to help large pharma, biotech, academics and clinicians unearth the intricacies of the GBA in demonstrating disease causation, and apply these findings within a clinical setting.
The BioTech Pharma Summit: AI Pharma 2018 will showcase the real world application and impact of AI, machine learning, deep learning and cognitive approaches to unlock insight and value along the drug discovery and development pipeline to deliver better medicines with better outcomes.
With the global Orphan Drug market expected to grow to $127 billion by 2018-2019, and another Rare Disease Day just having passed, there is a constantly growing awareness and interest for this industry, enabling more research to make a difference in patients’ lives.
The BioTech Pharma Summit: Liquid Biopsy 2018 focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), and protein-based circulating biomarkers.
A stage for the world’s leading experts in biorepositories, policy makers, and scientific actors to meet, in order to strengthen knowledge in biobanking as well as explore future advances in the field of biosampling for precision medicine, drug development and health research.